68ga labeled her2 affibody
HER2-positive Breast Cancer and Gastric Cancer
Xijing HospitalradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HER2-positive Breast Cancer and Gastric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
68ga labeled her2 affibody is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →